Results 71 to 80 of about 2,336 (164)

Editorial: Glycoconjugates in vaccines and immunotherapeutics

Frontiers in Immunology, 2022
Sachin Shivatare, Kumar Sanjiv, Raghavendra Kikkeri, Roberto Adamo   +3 more
openaire   +3 more sources

T-cell and B-cell dynamics following prime-boost immunization with W135 meningococcal conjugate vaccine in mice

Frontiers in Immunology
IntroductionGlycoconjugate vaccines convert T-cell-independent polysaccharides into T-cell-dependent antigens, but the cellular dynamics of prime‑boost responses remain incompletely defined.MethodsMice were immunized with the W135 meningococcal conjugate
Yahui Cheng, Yahui Cheng, Guiying Kou, Guiying Kou, Haifei Zhou, Haifei Zhou, Fanglei Liu, Fanglei Liu, Yunjin Wang, Yunjin Wang, Weiqi Wang, Weiqi Wang, Aili Wu, Aili Wu, Shuquan Luo, Shuquan Luo   +15 more
doaj   +1 more source

Semi-Synthetic Glycoconjugate Vaccine Lead Against Acinetobacter baumannii 17978. [PDF]

Angew Chem Int Ed Engl, 2022
Sianturi J, Priegue P, Hu J, Yin J, Seeberger PH.   +4 more
europepmc   +1 more source

GMMA as an Alternative Carrier for a Glycoconjugate Vaccine against Group A Streptococcus. [PDF]

Vaccines (Basel), 2022
Palmieri E, Kis Z, Ozanne J, Di Benedetto R, Ricchetti B, Massai L, Carducci M, Oldrini D, Gasperini G, Aruta MG, Rossi O, Kontoravdi C, Shah N, Mawas F, Micoli F.   +14 more
europepmc   +1 more source

A low-cost recombinant glycoconjugate vaccine confers immunogenicity and protection against enterotoxigenic Escherichia coli infections in mice. [PDF]

Front Mol Biosci, 2023
Williams AJ, Warfel KF, Desai P, Li J, Lee JJ, Wong DA, Nguyen PM, Qin Y, Sobol SE, Jewett MC, Chang YF, DeLisa MP.   +11 more
europepmc   +1 more source

Semisynthetic Glycoconjugate Vaccine Candidates against Escherichia coli O25B Induce Functional IgG Antibodies in Mice. [PDF]

JACS Au, 2022
Naini A, Bartetzko MP, Sanapala SR, Broecker F, Wirtz V, Lisboa MP, Parameswarappa SG, Knopp D, Przygodda J, Hakelberg M, Pan R, Patel A, Chorro L, Illenberger A, Ponce C, Kodali S, Lypowy J, Anderson AS, Donald RGK, von Bonin A, Pereira CL.   +20 more
europepmc   +1 more source

Harnessing galactose oxidase in the development of a chemoenzymatic platform for glycoconjugate vaccine design. [PDF]

J Biol Chem, 2022
Duke JA, Paschall AV, Glushka J, Lees A, Moremen KW, Avci FY.   +5 more
europepmc   +1 more source

Synthesis of Oligosaccharides Resembling the Streptococcus suis Serotype 18 Capsular Polysaccharide as a Basis for Glycoconjugate Vaccine Development. [PDF]

Org Lett, 2022
Singh RK, Sianturi J, Seeberger PH.
europepmc   +1 more source

Immunogenicity and safety of meningococcal vaccines, MenACWY-CRM and 4CMenB, in groups at increased risk for meningococcal disease

Expert Review of Vaccines
Introduction Individuals with immunocompromising conditions (e.g. asplenia, complement deficiency, HIV infection) or with high exposure to Neisseria meningitidis (e.g.
Shravani Bobde, Chiranjiwi Bhusal, Catherine A. Cosgrove, Woo-Yun Sohn   +3 more
doaj   +1 more source

Total Syntheses of Conjugation-Ready Repeating Units of Acinetobacter baumannii AB5075 for Glycoconjugate Vaccine Development. [PDF]

Chemistry, 2021
Zhang S, Seeberger PH.
europepmc   +1 more source